Based on a biological rationale suggesting that tumours with exceptionally high ER expression might exhibit maximal dependence on the ER pathway, we specifically hypothesised that an ER expression threshold of ≥90% would identify patients deriving superior benefit from CDK4/6 inhibition. This evidence concerns the gene ESR1 and neoplasm.